DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment

References

• Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Kamel FO. Factors involved in relapse of multiple sclerosis. J Microsc Ultrastruct. 2019;7(3):103–108.
   PubMedGoogle Scholar
• Maresova P, Valis M, Novotny M, et al. The direct costs of multiple sclerosis-study in the Czech Republic. Neurol Sci. 2018;39(12):2115–2121.
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66(7):1056–1060.
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628–1636.
   PubMed Web of Science ®Google Scholar
• Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol. 1999;46:197–206.
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet Lond Engl. 1998;352:1498–1504.
   Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Zhang J, Shi S, Zhang Y, et al. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2017;11(11):CD010968.
   PubMedGoogle Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59(10):1496–1506.
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33–41.
   PubMed Web of Science ®Google Scholar
• Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003. www.emro.who.int/ncd/Publications/adherence_report.pdf.
   Google Scholar
• Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551–554.
   PubMed Web of Science ®Google Scholar
• Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs J Am Assoc Neurosci Nurses. 2006;38:167–171.
   PubMedGoogle Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med. 2001;23(2):125–132.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69–77.
   PubMed Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568–576.
   PubMed Web of Science ®Google Scholar
• Vališ M, Šarláková J, Halúsková S, et al. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®. Expert Opin Drug Deliv. 2020;17(5):719–724.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–714.
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, et al. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis-results of the βPlus observational cohort study. J Neurol Sci. 2011;307(1–2):120–126.
   PubMed Web of Science ®Google Scholar
• Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence. 2011;5:173–180.
   PubMed Web of Science ®Google Scholar
• Bayas A, Japp G, Fulda U, et al. Injektionshilfen in der Basistherapie der Multiplen Sklerose: Erhebung bei Neurologen, MS-Betreuern und Patienten. Nervenheilkunde. 2010;29(01/02):57–62.
   Google Scholar
• Barone DA, Singer BA, Merkov L, et al. Survey of US patients with multiple sclerosis: comparison of the new electronic interferon beta-1b autoinjector (BETACONNECT™) with mechanical autoinjectors. Neurol Ther. 2016;5(2):155–167.
   PubMed Web of Science ®Google Scholar
• Tomlinson M, Boeru G, Milanov I, et al. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices Evid Res. 2013;6:175–184.
   Google Scholar
• Deftereos SN, Koutlas E, Koutsouraki E, et al. Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study. BMC Neurol. 2018;18(1):186.
   PubMedGoogle Scholar
• Limmroth V, Reischl J, Mann B, et al. Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Prefer Adherence. 2017;11:1325–1334.
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Schwab M, Pöhlau D, et al. Adherence to subcutaneous IFN β-1a in multiple sclerosis: final analysis of the non-interventional study READOUTsmart using the dosing log and readout function of RebiSmart®. Adv Ther. 2019;36(1):175–186.
   PubMed Web of Science ®Google Scholar
• de Sá J, Urbano G, Reis L. Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2010;26(9):2237–2242.
   PubMed Web of Science ®Google Scholar
• Koch C, Saake A, Schreiner T, et al. Patient satisfaction with the BETACONNECT™; autoinjector for interferon beta-1b. Patient Prefer Adherence. 2015;9:951–959.
   PubMed Web of Science ®Google Scholar
• Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12(8):1239–1250.
   PubMed Web of Science ®Google Scholar
• Devonshire VA, Verdun di Cantogno E. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Ther Deliv. 2011;2(11):1455–1465.
   PubMedGoogle Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012;12(1):7.
   PubMedGoogle Scholar